| Bioactivity | PGLa, a 21-residue peptide, is an antimicrobial peptide. PGLa is a member of the magainin family of antibiotic peptides found in frog skin and its secretions[1]. |
| Target | Anti-bacteria |
| Invitro | PGLa is a peptide starting with a glycine and ending with a leucine amide[1]. PGLa is bacteriostatic against both Gram-positive and Gram-negative bacteria with MIC values of 64 and 32 mg/L against S. aureus and E. coli, respectively[2]. |
| Name | PGLa |
| CAS | 102068-15-5 |
| Sequence | Gly-Met-Ala-Ser-Lys-Ala-Gly-Ala-Ile-Ala-Gly-Lys-Ile-Ala-Lys-Val-Ala-Leu-Lys-Ala-Leu-NH2 |
| Shortening | GMASKAGAIAGKIAKVALKAL-NH2 |
| Formula | C88H162N26O22S |
| Molar Mass | 1968.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bechinger B, et al. Structure and dynamics of the antibiotic peptide PGLa in membranes by solution and solid-state nuclear magnetic resonance spectroscopy. Biophys J. 1998 Feb;74(2 Pt 1):981-7. [2]. Radchenko DS, et al. Does a methionine-to-norleucine substitution in PGLa influence peptide-membrane interactions? Biochim Biophys Acta. 2016 Sep;1858(9):2019-27. |